Comparison of clinical characteristics and severity of COVID-19 with or without viral co-infection in hospitalized children.

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Journal of Infection and Chemotherapy Pub Date : 2024-09-11 DOI:10.1016/j.jiac.2024.09.009
Kensuke Shoji,Yusuke Asai,Shinya Tsuzuki,Nobuaki Matsunaga,Setsuko Suzuki,Noriko Iwamoto,Takanori Funaki,Isao Miyairi,Norio Ohmagari
{"title":"Comparison of clinical characteristics and severity of COVID-19 with or without viral co-infection in hospitalized children.","authors":"Kensuke Shoji,Yusuke Asai,Shinya Tsuzuki,Nobuaki Matsunaga,Setsuko Suzuki,Noriko Iwamoto,Takanori Funaki,Isao Miyairi,Norio Ohmagari","doi":"10.1016/j.jiac.2024.09.009","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nCo-infection with other pathogens can alter the severity and clinical outcomes of viral infections. However, the information regarding viral co-infections in pediatric coronavirus disease 2019 (COVID-19) cases is still limited.\r\n\r\nMETHODS\r\nThis is a nationwide, retrospective cohort study using the data from the COVID-19 Registry Japan. The pediatric (<18 years), laboratory confirmed, hospitalized COVID-19 patients in the Omicron variant of concern predominant period (January 2022 to January 2024) were included. Co-infection was investigated by multiplex PCR. We compared clinical characteristics, symptoms, severity, and outcomes between children with and without co-infection.\r\n\r\nRESULTS\r\nAmong 245 hospitalized pediatric COVID-19 patients, 78 (31.8 %) had co-infections. The patient backgrounds of the \"co-infection\" and \"SARS-CoV-2 alone\" groups were similar, although age distribution was different, with a lower number of patients over 12 years in the co-infection group (n = 2, 2.6 % vs. n = 29, 17.4 %; P < 0.001). Among the patients with co-infection, the most common pathogen was enterovirus/rhinovirus (51.3 %), followed by parainfluenza virus (23.1 %) and adenovirus (12.8 %). Patients with co-infection more commonly had respiratory symptoms, including SpO2 < 96 %, shortness of breath, runny nose, and wheezing. Requirement of non-invasive oxygen support was higher in the co-infection group (n = 27, 34.6 % vs. n = 28, 16.8 %, P = 0.006). By multivariable logistic regression analysis, co-infection and presence of any comorbidity were identified as significant risk factors for necessity of oxygen therapy (odds ratio [95 % confidence interval] 2.44 [1.29-4.63] and 3.99 [2.07-7.82], respectively).\r\n\r\nCONCLUSIONS\r\nViral co-infection may increase the risk of respiratory distress in pediatric COVID-19 patients.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"91 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2024.09.009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Co-infection with other pathogens can alter the severity and clinical outcomes of viral infections. However, the information regarding viral co-infections in pediatric coronavirus disease 2019 (COVID-19) cases is still limited. METHODS This is a nationwide, retrospective cohort study using the data from the COVID-19 Registry Japan. The pediatric (<18 years), laboratory confirmed, hospitalized COVID-19 patients in the Omicron variant of concern predominant period (January 2022 to January 2024) were included. Co-infection was investigated by multiplex PCR. We compared clinical characteristics, symptoms, severity, and outcomes between children with and without co-infection. RESULTS Among 245 hospitalized pediatric COVID-19 patients, 78 (31.8 %) had co-infections. The patient backgrounds of the "co-infection" and "SARS-CoV-2 alone" groups were similar, although age distribution was different, with a lower number of patients over 12 years in the co-infection group (n = 2, 2.6 % vs. n = 29, 17.4 %; P < 0.001). Among the patients with co-infection, the most common pathogen was enterovirus/rhinovirus (51.3 %), followed by parainfluenza virus (23.1 %) and adenovirus (12.8 %). Patients with co-infection more commonly had respiratory symptoms, including SpO2 < 96 %, shortness of breath, runny nose, and wheezing. Requirement of non-invasive oxygen support was higher in the co-infection group (n = 27, 34.6 % vs. n = 28, 16.8 %, P = 0.006). By multivariable logistic regression analysis, co-infection and presence of any comorbidity were identified as significant risk factors for necessity of oxygen therapy (odds ratio [95 % confidence interval] 2.44 [1.29-4.63] and 3.99 [2.07-7.82], respectively). CONCLUSIONS Viral co-infection may increase the risk of respiratory distress in pediatric COVID-19 patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比较住院儿童合并或不合并病毒感染 COVID-19 的临床特征和严重程度。
背景与其他病原体合并感染可改变病毒感染的严重程度和临床结果。方法这是一项全国性的回顾性队列研究,使用了日本 COVID-19 登记处的数据。研究纳入了实验室确诊的小儿(小于 18 岁)COVID-19 住院患者,这些患者处于 Omicron 变异关注的主要时期(2022 年 1 月至 2024 年 1 月)。通过多重 PCR 对合并感染进行了调查。结果在 245 名住院的小儿 COVID-19 患者中,78 人(31.8%)合并感染。合并感染 "组和 "单纯 SARS-CoV-2 感染 "组的患者背景相似,但年龄分布不同,合并感染组中 12 岁以上的患者人数较少(2 人,占 2.6%;29 人,占 17.4%;P < 0.001)。在合并感染的患者中,最常见的病原体是肠道病毒/鼻病毒(51.3%),其次是副流感病毒(23.1%)和腺病毒(12.8%)。合并感染的患者通常会出现呼吸道症状,包括 SpO2 < 96 %、气短、流鼻涕和喘息。合并感染组患者需要无创氧气支持的比例更高(n = 27,34.6 % vs. n = 28,16.8 %,P = 0.006)。通过多变量逻辑回归分析,共同感染和任何合并症的存在被确定为需要氧疗的重要风险因素(几率比[95% 置信区间]分别为 2.44 [1.29-4.63] 和 3.99 [2.07-7.82])。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Infection and Chemotherapy
Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
CiteScore
4.10
自引率
4.50%
发文量
303
审稿时长
47 days
期刊介绍: The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.
期刊最新文献
Evaluation of Legionella Diagnostic Prediction Score in patients with SARS-CoV-2 Omicron pneumonia. Encrusted pyelitis and hyperammonemia due to Corynebacterium urealyticum in a kidney transplant recipient. Teicoplanin 24-h loading dose regimen using a decision tree model to target serum trough concentration of 15-30 μg/mL: A retrospective study. Identification of causative and non-causative microorganisms of nephrostomy tube-associated pyelonephritis among patients with malignancy. Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1